Crispr Therapeutics AG (NASDAQ:CRSP) has been assigned a consensus recommendation of “Buy” from the eight research firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have given a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $25.88.
Several research analysts recently issued reports on CRSP shares. BidaskClub raised shares of Crispr Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday. Cann reissued a “hold” rating on shares of Crispr Therapeutics in a research report on Sunday, December 10th. Zacks Investment Research lowered shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday. SunTrust Banks raised shares of Crispr Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, January 23rd. Finally, Piper Jaffray Companies assumed coverage on shares of Crispr Therapeutics in a report on Friday, December 22nd. They set an “overweight” rating for the company.
In other news, Director Thomas Woiwode sold 1,700 shares of the firm’s stock in a transaction that occurred on Friday, November 24th. The shares were sold at an average price of $20.21, for a total transaction of $34,357.00. Following the completion of the sale, the director now owns 8,218 shares of the company’s stock, valued at $166,085.78. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Corp /De/ Celgene sold 1,112,446 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $18.98, for a total transaction of $21,114,225.08. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 2,234,504 shares of company stock valued at $44,388,553. Company insiders own 39.98% of the company’s stock.
Crispr Therapeutics (NASDAQ CRSP) opened at $39.45 on Monday. Crispr Therapeutics has a 52-week low of $11.63 and a 52-week high of $42.90. The stock has a market cap of $1,770.00 and a PE ratio of -123.28.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Wednesday, November 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.02). Crispr Therapeutics had a negative return on equity of 38.42% and a negative net margin of 466.58%. The business had revenue of $2.39 million during the quarter, compared to analyst estimates of $3.61 million. During the same period last year, the company earned ($2.77) EPS. The business’s revenue for the quarter was up 54.2% on a year-over-year basis. equities research analysts anticipate that Crispr Therapeutics will post -2.42 earnings per share for the current fiscal year.
WARNING: This article was originally published by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/29/crispr-therapeutics-ag-crsp-given-average-recommendation-of-buy-by-analysts.html.
Crispr Therapeutics Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.